FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 348:1503-1504 April 10, 2003 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: Oral bisphosphonates are effective for the prevention and treatment of osteoporosis. Powerful second- and third-generation parenteral bisphosphonates, including pamidronate and zoledronate, are also available for off-label use. Although rarely observed, mild hypocalcemia has been reported with this class of agents.¹ On the other hand, osteomalacia, as a result of vitamin D deficiency, is common, especially in elderly persons and those with malabsorptive states such as those due to gastric bypass, nontropical sprue, and cystic fibrosis.² A recent case illustrates a serious complication of bisphosphonate use in a patient with coexisting but occult osteomalacia.

A 52-year-old woman presented . . . [Full Text of this Article]

This article has been cited by other articles:

• Heaney, R. P. (2008). Calcium Supplementation and Incident Kidney Stone Risk: A Systematic Review. J. Am. Coll. Nutr. 27: 519-527 [Abstract] [Full Text]  
• Wang-Gillam, A., Miles, D. A., Hutchins, L. F. (2008). Evaluation of Vitamin D Deficiency in Breast Cancer Patients on Bisphosphonates. The Oncologist 13: 821-827 [Abstract] [Full Text]  
• de Nijs, R. N.J., Westgeest, A. A.A., Poole, K. E.S., Kaptoge, S., Reeve, J., Karam, R., Camm, J., McClung, M., Najib, M. A., Aziz, I., Chang, J. T., Black, D., Eriksen, E., Sellmeyer, D., Compston, J. (2007). Yearly zoledronic acid in postmenopausal osteoporosis.. NEJM 357: 711-712 [Full Text]  
• Poole, K. E.S., Loveridge, N., Rose, C. M., Warburton, E. A., Reeve, J. (2007). A Single Infusion of Zoledronate Prevents Bone Loss After Stroke. Stroke 38: 1519-1525 [Abstract] [Full Text]  
• Grigg, A. P., Shuttleworth, P., Reynolds, J., Schwarer, A. P., Szer, J., Bradstock, K., Hui, C., Herrmann, R., Ebeling, P. R. (2006). Pamidronate Reduces Bone Loss after Allogeneic Stem Cell Transplantation. J. Clin. Endocrinol. Metab. 91: 3835-3843 [Abstract] [Full Text]  
• Whyte, M. P. (2006). Paget's Disease of Bone. NEJM 355: 593-600 [Full Text]  
• Tanvetyanon, T., Stiff, P. J. (2006). Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 17: 897-907 [Abstract] [Full Text]  
• Poole, K. E. S., Loveridge, N., Barker, P. J., Halsall, D. J., Rose, C., Reeve, J., Warburton, E. A. (2006). Reduced Vitamin D in Acute Stroke. Stroke 37: 243-245 [Abstract] [Full Text]  
• Reid, I. R., Miller, P., Lyles, K., Fraser, W., Brown, J. P., Saidi, Y., Mesenbrink, P., Su, G., Pak, J., Zelenakas, K., Luchi, M., Richardson, P., Hosking, D. (2005). Comparison of a Single Infusion of Zoledronic Acid with Risedronate for Paget's Disease. NEJM 353: 898-908 [Abstract] [Full Text]  
• Rosen, C. J. (2005). Postmenopausal Osteoporosis. NEJM 353: 595-603 [Full Text]  
• Shaw, N J, Bishop, N J (2005). Bisphosphonate treatment of bone disease. Arch. Dis. Child. 90: 494-499 [Abstract] [Full Text]  
• Antoniucci, D. M., Black, D. M., Sellmeyer, D. E. (2005). Serum 25-Hydroxyvitamin D Is Unaffected by Multiple Freeze-Thaw Cycles. Clin. Chem. 51: 258-261 [Full Text]  
• Small, E. J. (2004). In Reply:. JCO 22: 2035-2035 [Full Text]  
• Breen, T. L., Shane, E. (2004). Prolonged Hypocalcemia After Treatment With Zoledronic Acid in a Patient With Prostate Cancer and Vitamin D Deficiency. JCO 22: 1531-1532 [Full Text]  
• Tanvetyanon, T., Choudhury, A. M (2004). Hypocalcemia and Azotemia Associated with Zoledronic Acid and Interferon Alfa. The Annals of Pharmacotherapy 38: 418-421 [Abstract] [Full Text]